Breaking News

Novo Nordisk Announces $372.5M Expansion in Monksland, Athlone, Ireland

The investment will support the upgrade and retrofit of the existing facility and enhance Novo Nordisk’s capacity to manufacture oral GLP-1s.

Author Image

By: Charlie Sternberg

Associate Editor

Novo Nordisk is expanding its tabletting facility in Monksland, Athlone, Ireland with a 432 million euro ($372.5 million) investment in order to provide additional manufacturing capacity for current and future Novo Nordisk GLP-1 treatments. The investment provides Novo Nordisk with additional manufacturing capabilities for oral products, enhances supply, and allows Ireland to serve as a critical hub for servicing markets outside the U.S. The investment will support the upgrade and retrofit of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters